Nonviral methods for siRNA delivery.

RNA interference (RNAi) as a mechanism to selectively degrade mRNA (mRNA) expression has emerged as a potential novel approach for drug target validation and the study of functional genomics. Small interfering RNAs (siRNA) therapeutics has developed rapidly and already there are clinical trials ongoing or planned. Although other challenges remain, delivery strategies for siRNA become the main hurdle that must be resolved prior to the full-scale clinical development of siRNA therapeutics. This review provides an overview of the current delivery strategies for synthetic siRNA, focusing on the targeted, self-assembled nanoparticles which show potential to become a useful and efficient tool in cancer therapy.

[1]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[2]  F. Szoka,et al.  Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.

[3]  Scott E. Martin,et al.  Applications of RNA interference in mammalian systems. , 2007, Annual review of genomics and human genetics.

[4]  A. Aigner.  Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo , 2006, Journal of biomedicine & biotechnology.

[5]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[6]  W. J. Irwin,et al.  Interaction of oligonucleotide-conjugates with the dipeptide transporter system in Caco-2 cells. , 1997, Biochemical pharmacology.

[7]  W. Wurst,et al.  RNA interference in mice. , 2007, Handbook of experimental pharmacology.

[8]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[9]  Leaf Huang,et al.  An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Leaf Huang,et al.  Surface‐Modified LPD Nanoparticles for Tumor Targeting , 2006, Annals of the New York Academy of Sciences.

[11]  S. Kawakami,et al.  Targeted delivery systems of small interfering RNA by systemic administration. , 2007, Drug metabolism and pharmacokinetics.

[12]  Leaf Huang,et al.  Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. , 2006, Molecular pharmaceutics.

[13]  D. Lewis,et al.  Systemic siRNA delivery via hydrodynamic intravascular injection. , 2007, Advanced drug delivery reviews.

[14]  Stephen P. Fox,et al.  The Design and Exogenous Delivery of siRNA for Post-transcriptional Gene Silencing , 2004, Journal of drug targeting.

[15]  Yadollah Omidi,et al.  Toxicogenomics of Non-viral Vectors for Gene Therapy: A Microarray Study of Lipofectin- and Oligofectamine-induced Gene Expression Changes in Human Epithelial Cells , 2003, Journal of drug targeting.

[16]  Dexi Liu,et al.  Computer-assisted hydrodynamic gene delivery. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  R. Surabhi,et al.  Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  F. Szoka,et al.  Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.

[19]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[20]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[21]  S. Akhtar,et al.  Nonviral delivery of synthetic siRNAs in vivo. , 2007, The Journal of clinical investigation.

[22]  S. Jana,et al.  RNA interference: potential therapeutic targets , 2004, Applied Microbiology and Biotechnology.

[23]  F. Wong-Staal,et al.  Development of new RNAi therapeutics. , 2007, Histology and histopathology.

[24]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[25]  D. Lewis,et al.  Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules , 2006, The journal of gene medicine.

[26]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[27]  Leaf Huang,et al.  Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[28]  A. D. Fougerolles.  Delivery vehicles for small interfering RNA in vivo. , 2008 .

[29]  Mette Ebbesen,et al.  Nanomedicine: Techniques, Potentials, and Ethical Implications , 2006, Journal of biomedicine & biotechnology.

[30]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[31]  S. Akhtar,et al.  Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. , 2007, Advanced drug delivery reviews.

[32]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[33]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[34]  Pradeep Tyagi,et al.  Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.

[35]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[36]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[37]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[38]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[39]  M. Hope,et al.  Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid , 2005, Journal of Pharmacology and Experimental Therapeutics.

[40]  Mouldy Sioud,et al.  Gene silencing by systemic delivery of synthetic siRNAs in adult mice. , 2003, Journal of molecular biology.

[41]  Leaf Huang,et al.  Non-viral is superior to viral gene delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Stephen P. Fox,et al.  Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes: In Vitro and In Vivo Studies , 2004, Journal of drug targeting.

[43]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[44]  M. Woodle,et al.  Harnessing in vivo siRNA delivery for drug discovery and therapeutic development , 2006, Drug Discovery Today.

[45]  J. Rossi,et al.  RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.

[46]  I. Ahmad,et al.  Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. , 2005, International journal of oncology.